Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Aug.19.2024
Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Accorto CEO Tom Beaudet and CSO Dr. Vince Angelico visit 2FIRSTS HQ for in-depth discussion on US e-cigarette industry.

On August 19, Tom Beaudet, CEO of the U.S. compliance company Accorto, and Dr. Vince Angelico, CSO (Chief Scientific Officer), visited the headquarters of 2FIRSTS to have a detailed discussion with Alan Zhao, co-founder and CEO of 2FIRSTS. Both sides explored the high-quality development of the e-cigarette industry in the American market.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Tom (third from the right), Vincent (fourth from the right), Alan Zhao (second from the right), and 2FIRSTS staff members posing for a photo. | Image source: 2FIRSTS

 

During the meeting, Alan Zhao warmly welcomed the arrival of the Accorto delegation and expressed appreciation for their professional insights in the field of PMTA compliance. Alan Zhao stated that with the U.S. Food and Drug Administration (FDA) continuously strengthening its regulation and enforcement of the e-cigarette market, compliance in the e-cigarette industry has become a crucial issue that companies cannot afford to overlook. In the face of market changes, companies must pay close attention to compliance services in order to ensure their sustainable and steady development.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
2024 Global New Tobacco Regulations Report" produced by 2FIRSTS|Image source: 2FIRSTS

 

In order to deepen mutual understanding and cooperation, Alan Zhao on behalf of 2FIRSTS presented Tom with the "2024 Global New Tobacco Regulation Report" (English version) produced by 2FIRSTS. The report provides a comprehensive analysis of the current global regulation of novel tobacco products and their development trends, offering valuable insights and guidance to the industry.

 

Tom highly praised 2FIRSTS' professionalism and contribution to the industry's development, and stated that he looks forward to deeper collaboration with 2FIRSTS in the e-cigarette compliance field in the future. Accorto, as a leading provider of PMTA compliance services, has been dedicated to assisting e-cigarette companies in FDA reviews to ensure products can legally enter the US market.

 

This exchange not only deepened mutual understanding between both parties, but also laid a solid foundation for future cooperation. 2FIRSTS and Accorto have both expressed their commitment to working together to promote the healthy and orderly development of the e-cigarette industry, providing global consumers with safer and more compliant e-cigarette products.

 

As a key media and research institution in the e-cigarette industry, 2FIRSTS will continue to leverage its influence within the industry to promote information exchange and knowledge sharing. We will work with partners like Accorto to contribute to the high-quality development of the e-cigarette industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24